Variable | OR (95% confidence interval) | P -value |
---|---|---|
Frequency of an assumed significant impairment caused by reactogenicity OR represents the odds ratio for a significant impairment after more vaccinations (i.e., after both vaccinations vs. after either one or none, after either one or both vaccinations vs. none) Based on 6747 vaccine combinations with complete information | ||
Age (31–40 vs. 18–30) | 0.77 (0.66–0.90) | .001 |
Age (41–50 vs. 18–30) | 0.64 (0.55–0.75) | < .001 |
Age (51–60 vs. 18–30) | 0.47 (0.40–0.55) | < .001 |
Age (> 61 vs. 18–30) | 0.34 (0.27–0.42) | < .001 |
Male gender | 0.73 (0.61–0.87) | < .001 |
Vaccine combination (ChAdOx + ChAdOx vs. BNT162b2 + BNT162b2) | 2.48 (2.08–2.94) | < .001 |
Frequency of an assumed significant impairment caused by reactogenicity OR represents the odds ratio for a significant impairment after more vaccinations (i.e., after both vaccinations vs. after either one or none, after either one or both vaccinations vs. none) Based on 6747 vaccine combinations with complete information | ||
Age (31–40 vs. 18–30) | 0.77 (0.66–0.90) | .001 |
Age (41–50 vs. 18–30) | 0.64 (0.55–0.75) | < .001 |
Age (51–60 vs. 18–30) | 0.47 (0.40–0.55) | < .001 |
Age (> 61 vs. 18–30) | 0.34 (0.27–0.42) | < .001 |
Male gender | 0.73 (0.61–0.87) | < .001 |
Vaccine combination (ChAdOx + ChAdOx vs. BNT162b2 + BNT162b2) | 2.48 (2.08–2.94) | < .001 |
Vaccine combination (mRNA-1273 + mRNA-1273 vs. ChAdOx + ChAdOx) | 1.13 (0.08–1.58) | ns |
Vaccine combination (ChAdOx + BNT162b/ mRNA-1273 vs. mRNA-1273 + mRNA-1273) | 1.72 (1.25–2.37) | < .001 |
Male gender × vaccine combination (ChAdOx + ChAdOx vs. BNT162b2 + BNT162b2) | 1.28 (0.91–1.80) | ns |
Male gender × vaccine combination (mRNA-1273 + mRNA-1273 vs. ChAdOx + ChAdOx) | 0.75 (0.38–1.49) | ns |
Male gender × vaccine combination (ChAdOx + BNT162b/ mRNA-1273 vs. mRNA-1273 + mRNA-1273) | 1.06 (0.56–2.01) | ns |
Frequency of incapacity to work of one or more days OR represents the odds ratio for incapacity to after more vaccinations (i.e., after both vaccinations vs. after either one or none, after either one or both vaccinations vs. none) on 5153 vaccine combinations with complete information | ||
Age (31–40 vs. 18–30) | 0.72 (0.60–0.86) | < .001 |
Age (41–50 vs. 18–30) | 0.56 (0.47–0.67) | < .001 |
Age (51–60 vs. 18–30) | 0.43 (0.36–0.51) | < .001 |
Age (> 61 vs. 18–30) | 0,42 (0.31–0.56) | < .001 |
Male gender | 0.73 (0.58–0.92) | .008 |
Vaccine combination (mRNA-1273 + mRNA-1273 vs. BNT162b2 + BNT162b2) | 1.64 (1.09–2.46) | < .001 |
Vaccine combination (ChAdOx + ChAdOx vs. mRNA-1273 + mRNA-1273) | 1.43 ( 0.92–2.23) | ns |
Vaccine combination (ChAdOx + BNT162b/ mRNA-1273 vs. ChAdOx + ChAdOx) | 1.57 (1.24–1.99) | < .001 |
Male gender × vaccine combination (mRNA-1273 + mRNA-1273 vs BNT162b2 + BNT162b2) | 2.25 (1.00–5.06) | .050 |
Male gender × vaccine combination (ChAdOx + ChAdOx vs. mRNA-1273 + mRNA-1273) | 0.51 (0.21–1.23) | ns |
Male gender × vaccine combination (ChAdOx + BNT162b/ mRNA-1273 vs. ChAdOx + ChAdOx) | 1.21 (0.76–1.94) | ns |
Vaccine combination (mRNA-1273 + mRNA-1273 vs. ChAdOx + ChAdOx) | 1.13 (0.08–1.58) | ns |
Vaccine combination (ChAdOx + BNT162b/ mRNA-1273 vs. mRNA-1273 + mRNA-1273) | 1.72 (1.25–2.37) | < .001 |
Male gender × vaccine combination (ChAdOx + ChAdOx vs. BNT162b2 + BNT162b2) | 1.28 (0.91–1.80) | ns |
Male gender × vaccine combination (mRNA-1273 + mRNA-1273 vs. ChAdOx + ChAdOx) | 0.75 (0.38–1.49) | ns |
Male gender × vaccine combination (ChAdOx + BNT162b/ mRNA-1273 vs. mRNA-1273 + mRNA-1273) | 1.06 (0.56–2.01) | ns |
Frequency of incapacity to work of one or more days OR represents the odds ratio for incapacity to after more vaccinations (i.e., after both vaccinations vs. after either one or none, after either one or both vaccinations vs. none) on 5153 vaccine combinations with complete information | ||
Age (31–40 vs. 18–30) | 0.72 (0.60–0.86) | < .001 |
Age (41–50 vs. 18–30) | 0.56 (0.47–0.67) | < .001 |
Age (51–60 vs. 18–30) | 0.43 (0.36–0.51) | < .001 |
Age (> 61 vs. 18–30) | 0,42 (0.31–0.56) | < .001 |
Male gender | 0.73 (0.58–0.92) | .008 |
Vaccine combination (mRNA-1273 + mRNA-1273 vs. BNT162b2 + BNT162b2) | 1.64 (1.09–2.46) | < .001 |
Vaccine combination (ChAdOx + ChAdOx vs. mRNA-1273 + mRNA-1273) | 1.43 (0.92–2.23) | ns |
Vaccine combination (ChAdOx + BNT162b/ mRNA-1273 vs. ChAdOx + ChAdOx) | 1.57 (1.24–1.99) | < .001 |
Male gender × vaccine combination (mRNA-1273 + mRNA-1273 vs BNT162b2 + BNT162b2) | 2.25 (1.00–5.06) | .050 |
Male gender × vaccine combination (ChAdOx + ChAdOx vs. mRNA-1273 + mRNA-1273) | 0.51 (0.21–1.23) | ns |
Male gender × vaccine combination (ChAdOx + BNT162b/ mRNA-1273 vs. ChAdOx + ChAdOx) | 1.21 (0.76–1.94) | ns |